Dopamine D2 receptor occupancy and cognition in schizophrenia: Analysis of the CATIE data

Schizophrenia Bulletin

Volumn 39, Issue 3, 2013, Pages 564-574

  Sakurai, Hitoshi ^a   Bies, Robert R ^b,c,d   Stroup, Scott T ^e   Keefe, Richard S E ^f   Rajji, Tarek K ^b,g   Suzuki, Takefumi ^a   Mamo, David C ^b,g   Pollock, Bruce G ^b,g   Watanabe, Koichiro ^a   Mimura, Masaru ^a   Uchida, Hiroyuki ^a,b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c INDIANA UNIVERSITY   (United States)

^d Indiana Clinical and Translational Sciences Institute   (United States)

^e Columbia University ^*  (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

antipsychotic; cognition; dopamine; olanzapine; risperidone; schizophrenia; ziprasodine

Indexed keywords

DOPAMINE 2 RECEPTOR; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; DRD2 PROTEIN, HUMAN; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ALERTNESS; ARTICLE; COGNITION; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR OCCUPANCY; SCHIZOPHRENIA; THINKING; VERBAL MEMORY; WORKING MEMORY; ADOLESCENT; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION DISORDERS; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PIPERAZINES; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES; YOUNG ADULT;

EID: 84876592957     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr189     Document Type: Article

References (53)

1. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321-330. (Pubitemid 26074706)
2. Elie D, Poirier M, Chianetta J, Durand M, Gregoire C, Grignon S. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol. 2010;24:1037-1044.
3. Knowles EE, David AS, Reichenberg A. Processing speed deficits in schizophrenia: reexamining the evidence. Am J Psychiatry. 2010;167:828-835.
4. Hori H, Noguchi H, Hashimoto R, et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res. 2006;86:138-146. (Pubitemid 44234045)
5. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25:201-222. (Pubitemid 29272501)
6. Minzenberg MJ, Poole JH, Benton C, Vinogradov S. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004;161:116-124. (Pubitemid 38419316)
7. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176-184. (Pubitemid 32116511)
8. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8:457-472. (Pubitemid 41002500)
9. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64: 633-647. (Pubitemid 46878665)
10. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005;162:1888-1895. (Pubitemid 41428618)
11. Volkow ND, Gur RC, Wang GJ, et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry. 1998;155:344-349. (Pubitemid 28114890)
12. Uchida H, Rajji TK, Mulsant BH, et al. D2 receptor blockade by risperidone correlates with attention deficits in latelife schizophrenia. J Clin Psychopharmacol. 2009;29:571-575.
13. Lawrence AD, Weeks RA, Brooks DJ, et al. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain. 1998;121(pt 7): 1343-1355. (Pubitemid 28327410)
14. Glickstein SB, Hof PR, Schmauss C. Mice lacking dopamine D2 and D3 receptors have spatial working memory deficits. J Neurosci. 2002;22:5619-5629. (Pubitemid 35386483)
15. Glickstein SB, Desteno DA, Hof PR, Schmauss C. Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention. Cereb Cortex. 2005;15:1016-1024. (Pubitemid 40848070)
16. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:318-325.
17. Bigos KL, Bies RR, Pollock BG. Population pharmacokinetics in geriatric psychiatry. Am J Geriatr Psychiatry. 2006; 14:993-1003. (Pubitemid 44936991)
18. Uchida H, Pollock BG, Bies RR, Mamo DC. Predicting age-specific dosing of antipsychotics. Clin Pharmacol Ther. 2009;86:360-362.
19. Feng Y, Pollock BG, Coley K, et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008;66:629-639.
20. Wessels AM, Bies RR, Pollock BG, et al. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol. 2011;51: 1587-1591.
21. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48: 157-165.
22. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:497-502.
23. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29: 15-31. (Pubitemid 36871054)
24. Keefe RS, Mohs RC, Bilder RM, et al. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull. 2003;29: 45-55. (Pubitemid 36871056)
25. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006;31:2033-2046.
26. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5: 445-479. (Pubitemid 8224518)
27. Cha TA, Beall E, Irvine B, et al. At least five related, but distinct, hepatitis C viral genotypes exist. Proc Natl Acad Sci USA. 1992;89:7144-7148.
28. Ismail Z, Wessels AM, Uchida H, et al. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry. 2012;20:53-60.
29. Boulougouris V, Tsaltas E. Serotonergic and dopaminergic modulation of attentional processes. Prog Brain Res. 2008; 172:517-542.
30. Cole BJ, Robbins TW. Effects of 6-hydroxydopamine lesions of the nucleus accumbens septi on performance of a 5-choice serial reaction time task in rats: implications for theories of selective attention and arousal. Behav Brain Res. 1989; 33:165-179. (Pubitemid 19141065)
31. Korchounov A, Ziemann U. Neuromodulatory neurotransmitters influence LTP-like plasticity in human cortex: a pharmaco-TMS study. Neuropsychopharmacology. 2011;36:1894-1902.
32. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1081-1090. (Pubitemid 37464954)
33. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol. 1995;15(1 suppl 1):19-23.
34. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia. Am J Psychiatry. 2000;157:514-520. (Pubitemid 30191189)
35. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992; 49:538-544.
36. Leeson VC, Barnes TR, Harrison M, et al. The relationship between IQ, memory, executive function, and processing speed in recent-onset psychosis: 1-year stability and clinical outcome. Schizophr Bull. 2010;36:400-409.
37. Niendam TA, Bearden CE, Rosso IM, et al. A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings. Am J Psychiatry. 2003;160: 2060-2062. (Pubitemid 39619649)
38. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007;64:532-542. (Pubitemid 46718286)
39. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother. 2002;36:839-851. (Pubitemid 34517416)
40. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther. 2011;17:118-132.
41. Kassahun K, Mattiuz E, Nyhart E Jr, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997;25:81-93. (Pubitemid 27045138)
42. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
43. Agid O, Mamo D, Ginovart N, et al. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response- A doubleblind PET study in schizophrenia. Neuropsychopharmacology. 2007;32:1209-1215. (Pubitemid 46788848)
44. Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ. Serotonin and human cognitive performance. Curr Pharm Des. 2006;12:2473-2486. (Pubitemid 44026030)
45. Gonzalez-Burgos I, Feria-Velasco A. Serotonin/dopamine interaction in memory formation. Prog Brain Res. 2008;172: 603-623.
46. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818-825. (Pubitemid 38625334)
47. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293. (Pubitemid 29077120)
48. Heinik J. Effects of trihexyphenidyl on MMSE and CAMCOG scores of medicated elderly patients with schizophrenia. Int Psychogeriatr. 1998;10:103-108. (Pubitemid 28284564)
49. Gelenberg AJ, Van Putten T, Lavori PW, et al. Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol. 1989;9:180-185. (Pubitemid 19155158)
50. Bottiggi KA, Salazar JC, Yu L, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry. 2006;14:980-984. (Pubitemid 44706417)
51. Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53:2195-2201. (Pubitemid 43001205)
52. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a communitybased sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60:198-203. (Pubitemid 36173127)
53. Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am J Geriatr Psychiatry. 2005;13:535-538.